SCHEMBL1640848

SCHEMBL1640848

O=C(Nc1cccc2ccccc12)c1cn(Cc2ccccc2)c(=O)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 9/20 0.50
CNR1 P21554 4/20 0.48
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HSD17B10 Q99714 2/20 0.47
LMNA P02545 2/20 0.47
USP2 O75604 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPK1 P28482 1/20 0.47
CHRNB2 P17787 1/20 0.47
CHRNB4 P30926 1/20 0.47
CHRNA3 P32297 1/20 0.47
CHRNA4 P43681 1/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1642053 0.82 MAPT (0.59) KDM4EALDH1A1HSD17B10LMNARAB9A
SCHEMBL1640326 0.80 HSP90AA1 (0.58) CNR2KDM4EALDH1A1HSD17B10LMNA
SCHEMBL1640573 0.78 BRD4 (0.65) ALDH1A1LMNARAB9AMAPTGAA
SCHEMBL1642062 0.78 NPC1 (0.51) LMNANPC1RAB9AKMT2A
SCHEMBL1642063 0.77 KDR (0.56) KDM4EALDH1A1HSD17B10NPC1RAB9A
SCHEMBL1641834 0.77 EGLN3 (0.71) CNR2CNR1KDM4EALDH1A1HSD17B10
SCHEMBL1640352 0.76 LMNA (0.55) KDM4EALDH1A1LMNAKMT2AMEN1
SCHEMBL1641962 0.76 NPC1 (0.54) KDM4EALDH1A1ALOX15CHRNB2CHRNB4
SCHEMBL1641827 0.75 BRD4 (0.57) KMT2AMEN1MAPT
SCHEMBL1641964 0.75 KDM4E (0.54) KDM4EALDH1A1LMNAUSP2MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 CNR2 2738/4885CNR1 2636/4885KDM4E 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.